Aerie Pharmaceuticals Inc (NASDAQ:AERI) Can’t Be Less Risky. Short Interest Decreased

March 17, 2018 - By Hazel Jackson

 Aerie Pharmaceuticals Inc (NASDAQ:AERI) Can't Be Less Risky. Short Interest Decreased

Investors sentiment increased to 1.73 in 2017 Q3. Its up 0.56, from 1.17 in 2017Q2. It increased, as 14 investors sold Aerie Pharmaceuticals, Inc. shares while 41 reduced holdings. 26 funds opened positions while 69 raised stakes. 34.42 million shares or 8.89% more from 31.61 million shares in 2017Q2 were reported.
American Group Inc invested in 21,765 shares. Creative Planning reported 4,200 shares. Rhenman & Prns Asset Mgmt Ab has invested 0.75% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Principal Group Inc owns 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 5,643 shares. Prudential Fincl, New Jersey-based fund reported 56,520 shares. The New York-based Suffolk Mgmt Ltd has invested 1.82% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Morgan Stanley holds 0% or 100,012 shares. Partner Invest Mngmt L P holds 1.46% or 31,702 shares in its portfolio. Harvey invested 0.49% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Dekabank Deutsche Girozentrale, a Germany-based fund reported 15,900 shares. State Street Corporation accumulated 794,614 shares. Broadfin Capital Ltd Co holds 64,800 shares. One Trading Ltd Partnership invested in 0% or 281 shares. Fincl Consulate Incorporated has 0.49% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 18,500 shares. Cubist Systematic Strategies Ltd Com invested in 0.02% or 8,106 shares.

The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) registered a decrease of 0.35% in short interest. AERI’s total short interest was 3.94M shares in March as published by FINRA. Its down 0.35% from 3.95M shares, reported previously. With 488,600 shares average volume, it will take short sellers 8 days to cover their AERI’s short positions. The short interest to Aerie Pharmaceuticals Inc’s float is 14.68%.

The stock increased 0.87% or $0.5 during the last trading session, reaching $57.95. About 386,161 shares traded or 1.48% up from the average. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 180.20% since March 17, 2017 and is uptrending. It has outperformed by 163.50% the S&P500.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.29 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Among 15 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals has $10000 highest and $30 lowest target. $73.62’s average target is 27.04% above currents $57.95 stock price. Aerie Pharmaceuticals had 49 analyst reports since August 7, 2015 according to SRatingsIntel. H.C. Wainwright initiated Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on Tuesday, September 20 with “Buy” rating. The firm earned “Buy” rating on Friday, February 16 by H.C. Wainwright. As per Wednesday, August 2, the company rating was maintained by Cowen & Co. The stock has “Buy” rating by Stifel Nicolaus on Thursday, July 27. As per Thursday, September 15, the company rating was maintained by Cantor Fitzgerald. The firm has “Buy” rating given on Friday, June 3 by Cantor Fitzgerald. RBC Capital Markets maintained the shares of AERI in report on Thursday, September 15 with “Outperform” rating. Canaccord Genuity maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on Monday, October 16 with “Buy” rating. Cantor Fitzgerald maintained the stock with “Buy” rating in Thursday, November 16 report. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Cantor Fitzgerald on Monday, December 18.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: